We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03361969
Recruitment Status : Completed
First Posted : December 5, 2017
Last Update Posted : June 18, 2021
Sponsor:
Information provided by (Responsible Party):
Pantarhei Oncology B.V.

Brief Summary:
This is a phase IIa, double-blind, randomised, placebo-controlled, multi-center study to evaluate the effects of estetrol on testosterone suppression and quality of life in prostate cancer patients treated with an LHRH agonist. Patients will be treated with estetrol or placebo for 6 months.

Condition or disease Intervention/treatment Phase
Prostatic Neoplasm Drug: Estetrol Drug: Placebo Oral Tablet Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 63 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomised, Placebo-controlled, Multi-center Study to Evaluate Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist.
Actual Study Start Date : April 16, 2018
Actual Primary Completion Date : May 15, 2020
Actual Study Completion Date : May 15, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Active Comparator: estetrol Drug: Estetrol
estetrol formulated in tablets

Placebo Comparator: placebo Drug: Placebo Oral Tablet
placebo tablets




Primary Outcome Measures :
  1. Difference in total testosterone levels between treatment groups [ Time Frame: 168 days ]
    Serum concentrations of total testosterone will be listed and summarized descriptively by treatment group. Nadir and time to nadir will be described using summary statistics.

  2. Difference in free testosterone levels between treatment groups [ Time Frame: 168 days ]
    Serum concentrations of free testosterone will be listed and summarized descriptively by treatment group. Nadir and time to nadir will be described using summary statistics.

  3. Difference in mean daily hot flushes score between treatment groups [ Time Frame: 168 days ]
    The number and severity in hot flushes will be assessed by means of a diary in which the patients records his hot flushes for 7 days.


Secondary Outcome Measures :
  1. Change from baseline in endocrine parameters, adrenal androgen, dihydrotestosterone (DHT) and Sex Hormone Binding Globulin (SHBG) [ Time Frame: 168 days ]
    Effects on endocrine parameters (Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH) and Estradiol (E2), adrenal androgens (Dehydroepiandrosterone sulfate (DHEAS)), dihydrotestosterone (DHT) and SHBG will be evaluated. Actual values at baseline and at the scheduled visits, as well as change from baseline values at the post-baseline visits will be described using summary statistics and graphs. Difference between the treatment groups will be evaluated.

  2. Change from baseline in prostate-specific antigen (PSA) response [ Time Frame: 168 days ]
    Effects on PSA response will be evaluated. Actual values at baseline and at the scheduled visits, as well as change from baseline and percentage change from baseline values at the post-baseline visits will be described using summary statistics and graphs. Nadir and time to nadir will be described using summary statistics. Difference between the treatment groups will be evaluated.

  3. Questionnaire on Quality of Life [ Time Frame: 168 days ]

    Effects on FACT-P questionnaire will be evaluated. FACT-P includes a 27-item "core" quality of life measure (FACT-G) grouped into 4 sub-scales: physical, social/family, emotional, and functional well-being. The prostate cancer-specific subscale contains an additional 12 items; 10 of which are prostate cancer specific physical problems. Items are rated on a 5-item Likert scale, from 0, "not at all", to 4, "very much". Total range of scores is from 0 - 156. Higher scores indicate higher degree of functioning and better quality of life.

    Total FACT-P scores, FACT-P general health subscale score (FACT-G) total score and all FACT-P subscale scores will be described at the scheduled visits using summary statistics and graphs. Differences between the treatment groups will be evaluated.


  4. Change from baseline in lipids [ Time Frame: 168 days ]
    Effects on total cholesterol, triglycerides, High Density Lipoprotein (HDL) cholesterol and Low Density Lipoprotein (LDL) cholesterol will be evaluated. Actual values at baseline and at the schedule visits as well as change from baseline values at the post-baseline visits will be described using summary statistics and graphs. Differences between the treatment groups will be evaluated.

  5. Change from baseline in bone turnover markers [ Time Frame: 168 days ]
    Effects on bone turnover markers osteocalcin and type I collagen telopeptide (CTX-1) will be evaluated. Actual values at baseline and at the schedule visits as well as change from baseline values at the post-baseline visits will be described using summary statistics and graphs. Differences between the treatment groups will be evaluated.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male patients with prostate cancer, qualifying for treatment with a LHRH agonist;
  • Age ≥ 18 years;
  • Body mass index (BMI) between ≥ 18.0 and ≤ 35.0 kg/m2 (inclusive);
  • Reasonable physical and mental health as judged by the Investigator determined by physical examination, clinical laboratory assessments and vital signs;
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1;
  • Life expectancy of at least 2 years.

Exclusion Criteria:

  • Current or prior (during the last 12 months) hormonal therapy, immunotherapy or chemotherapy for prostate cancer. Allowed are 14 days concomitant treatment with an anti-androgen to prevent the flare-up, radiotherapy and low dose radiation to prevent gynecomastia;
  • History of deep vein thrombosis, pulmonary embolism, or cerebrovascular accident. However, patients with such history using anticoagulants for ≥ 6 months are eligible for the study provided anticoagulant treatment is continued throughout the whole study;
  • History of myocardial infarction or a coronary vascular procedure (e.g. percutaneous coronary intervention, coronary artery bypass graft). However, patients with such history using anticoagulants for ≥ 6 months are eligible for the study provided anticoagulant treatment is continued throughout the whole study;
  • Patients who have unstable angina or clinical congestive heart failure;
  • A defect in the blood coagulation system, assessed at screening: deficiencies in AT-III, protein C and protein S and elevated factor VIII;
  • Mutation in coagulation factor II and/or positive for factor V Leiden, assessed at screening;
  • Diabetes mellitus with poor glycaemic control in the past 6 months (haemoglobin A1c (HbA1c) above 7.5%);
  • Known primary hyperlipidaemias (Fredrickson);
  • Disturbance of liver function: cholestatic jaundice, a history of jaundice due to previous estrogen use, Rotor syndrome and Dubin-Johnson syndrome;
  • Known porphyria;
  • Uncontrolled hypertension, i.e. systolic blood pressure 160 mmHg and/or diastolic blood pressure 100 mmHg in the last 6 months with or without medication.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03361969


Locations
Layout table for location information
Netherlands
Andros Men's Health Institutes
Arnhem, Gelderland, Netherlands, 6803 AA
Noord West Ziekenhuis
Alkmaar, Netherlands
St Antonius Ziekenhuis
Nieuwegein, Netherlands
CWZ
Nijmegen, Netherlands
Antonius Ziekenhuis
Sneek, Netherlands
Isala Zwolle
Zwolle, Netherlands
Sponsors and Collaborators
Pantarhei Oncology B.V.
Layout table for additonal information
Responsible Party: Pantarhei Oncology B.V.
ClinicalTrials.gov Identifier: NCT03361969    
Other Study ID Numbers: PR3109
First Posted: December 5, 2017    Key Record Dates
Last Update Posted: June 18, 2021
Last Verified: June 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pantarhei Oncology B.V.:
quality of life
hot flushes
prostate cancer
testosterone
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases